NEWARK, Calif.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing neuromodulators for use in treating aesthetic and therapeutic
conditions, today announced that Lauren Silvernail has resigned as
Revance's Chief Financial Officer and Chief Business Officer, effective
as of May 29, 2018, to pursue a Chief Financial Officer role at an
aesthetics company in Orange County, California, where she resides. Her
departure is not based on any disagreement with the company's accounting
principles or practices, internal controls or financial statement
disclosures.
Following Ms. Silvernail's resignation, certain members of management
and the Company's existing finance team will assume the duties and
responsibilities of the office on an interim basis.
Revance is initiating a search for its next Chief Financial Officer, who
will play an important role as the Company prepares for the
commercialization of its lead product candidate, DaxibotulinumtoxinA for
Injection (RT002).
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and therapeutic
conditions, including muscle movement disorders and pain. The company's
lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is
currently in development for the treatment of glabellar lines, cervical
dystonia and plantar fasciitis, with plans to initiate studies in upper
limb spasticity and chronic migraine. RT002 has the potential to be the
first long-acting neuromodulator. Revance has developed a proprietary,
stabilizing excipient peptide technology designed to create novel,
differentiated therapies. The company has a comprehensive pipeline based
upon its peptide technology, including injectable and topical
formulations of daxibotulinumtoxinA. More information on Revance may be
found at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180529005411/en/
INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert,
714-325-3584
jherbert@revance.com
or
Burns
McClellan, Inc.:
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
MEDIA
General
Media:
TOGORUN:
Mariann Caprino, 917-242-1087
m.caprino@togorun.com
or
Trade
Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com
Source: Revance Therapeutics, Inc.
News Provided by Acquire Media